Cancer trials versus the real world in the United States

Annals of Surgery

Volumn 254, Issue 3, 2011, Pages 438-443

  Al Refaie, Waddah B ^a   Vickers, Selwyn M ^a   Zhong, Wei ^a   Parsons, Helen ^a   Rothenberger, David ^a   Habermann, Elizabeth B ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGE; AGED; CANCER PATIENT; CANCER REGISTRY; CANCER RESEARCH; CANCER STAGING; CLINICAL TRIAL (TOPIC); CONFERENCE PAPER; CONTROLLED STUDY; DIGESTIVE SYSTEM CANCER; FEMALE; HEALTH INSURANCE; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; PATIENT PARTICIPATION; PRIORITY JOURNAL; RACE DIFFERENCE; RETROSPECTIVE STUDY; TREND STUDY; UNITED STATES; ANUS CANCER; BREAST CANCER; CANCER SURGERY; CAUCASIAN; COLON CANCER; EARLY CANCER; ESOPHAGUS CANCER; LIVER CANCER; MELANOMA; NEGRO; NEOPLASM; PANCREAS CANCER; POPULATION RESEARCH; PREDICTOR VARIABLE; RECTUM CANCER; SOFT TISSUE CANCER; STOMACH CANCER;

AFRICAN AMERICANS; AGE DISTRIBUTION; AGED; CALIFORNIA; CLINICAL TRIALS AS TOPIC; COHORT STUDIES; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HEALTH SERVICES ACCESSIBILITY; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; NEOPLASMS; PATIENT SELECTION; POVERTY; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 80052286823     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0b013e31822a7047     Document Type: Conference Paper

References (38)

1. Rothenberger DA. Evidence-based practice requires evidence. Br J Surg. 2004;91(11):1387-1388. (Pubitemid 39518072)
2. Peto R, Collins R, Gray R. Large-scale randomized evidence: large, simple trials and overviews of trials. Ann N Y Acad Sci. 1993;703:314-340. (Pubitemid 24149558)
3. Peto R, Baigent C. Trials: the next 50 years. Large scale randomised evidence of moderate benefits. BMJ. 1998;317(7167):1170-1171.
4. Brennan MF. Commentary: randomized controlled trials. Surg Oncol Clin N Am. 2010;19(1):xix-xx.
5. Begg CB. Cancer clinical trials in the USA: patient eligibility, generalizability of results and technology transfer. Bull Cancer. 1987;74(2):197-203. (Pubitemid 17097368)
6. Begg CB, Engstrom PF. Eligibility and extrapolation in cancer clinical trials. J Clin Oncol. 1987;5(6):962-968.
7. Begg CB, Pocock SJ, Freedman L, et al. State of the art in comparative cancer clinical trials. Cancer. 1987;60(11):2811-2815. (Pubitemid 17161817)
8. Rothwell PM. External validity of randomised controlled trials: "to whom do the results of this trial apply?" Lancet. 2005;365(9453):82-93. (Pubitemid 40082150)
9. Elting LS, Cooksley C, Bekele BN, et al. Generalizability of cancer clinical trial results: prognostic differences between participants and nonparticipants. Cancer. 2006;106(11):2452-2458. (Pubitemid 43787670)
10. Ford JG, Howerton MW, Lai GY, et al. Barriers to recruiting underrepresented populations to cancer clinical trials: a systematic review. Cancer. 2008;112(2):228-242.
11. Hutchins LF, Unger JM, Crowley JJ, et al. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med. 1999;341(27):2061-2067. (Pubitemid 30035956)
12. Murthy VH, Krumholz HM, Gross CP. Participation in cancer clinical trials: race-, sex-, and age-based disparities. JAMA. 2004;291(22):2720-2726. (Pubitemid 38725421)
13. Newman LA, Roff NK, Weinberg AD. Cancer clinical trials accrual: missed opportunities to address disparities and missed opportunities to improve outcomes for all. Ann Surg Oncol. 2008;15(7):1818-1819.
14. Stewart JH, Bertoni AG, Staten JL, et al. Participation in surgical oncology clinical trials: gender-, race/ethnicity-, and age-based disparities. Ann Surg Oncol. 2007;14(12):3328-3334. (Pubitemid 350160101)
15. Swanson GM, Bailar JC III. Selection and description of cancer clinical trials participants-science or happenstance? Cancer. 2002;95(5):950-959. (Pubitemid 34925343)
16. National Institutes of Health. NIH Guidelines on the Inclusion of Women and Minorities As Subjects in Clinical Research, 1993. In: NIH Guide. Vol. 23, Number 11. Bethesda, MD: National Institutes of Health; 1994.
17. Smedley BD, Adrienne YS, Nelson AR, eds. Unequal Treatment: Confronting Racial and Ethnic Disparities in Health Care. Washington, DC: The National Academies Press; 2003.
18. Nass SJ,Moses HL,Mendelsohn J, eds. A National Cancer Clinical Trials System for the 21st Century: Reinvigorating the NCI Cooperative Group Program. Washington, DC: The National Academies Press; 2010.
19. Dilts DM, Sandler AB. Invisible barriers to clinical trials: the impact of structural, infrastructural, and procedural barriers to opening oncology clinical trials. J Clin Oncol. 2006;24(28):4545-4552. (Pubitemid 46630949)
20. Meyer RM. Generalizing the results of cancer clinical trials. J Clin Oncol. 2010;28(2):187-189.
21. Ayanian JZ, Zaslavsky AM, Fuchs CS, et al. Use of adjuvant chemotherapy and radiation therapy for colorectal cancer in a population-based cohort. J Clin Oncol. 2003;21(7):1293-1300. (Pubitemid 46606406)
22. Jemal A, Ward E, Hao Y, et al. Trends in the leading causes of death in the United States, 1970-2002. JAMA. 2005;294(10):1255-1259. (Pubitemid 41352114)
23. Baquet CR, Mishra SI, Weinberg AD. A descriptive analysis of state legislation and policy addressing clinical trials participation. J Health Care Poor Underserved. 2009;20(2 Suppl):24-39.
24. Herrera AP, Snipes SA, King DW, et al. Disparate inclusion of older adults in clinical trials: priorities and opportunities for policy and practice change. Am J Public Health. 2010;100(Suppl 1):S105-S112.
25. Spiker CA, Weinberg AD. Policies to address disparities in clinical trials: the EDICT Project. J Cancer Educ. 2009;24(Suppl 2):S39-S49.
26. NCCN Guidelines: National Comprehensive Cancer Network. http://www.nccn.org/index.asp. Published 2011.
27. Wong SL, Morton DL, Thompson JF, et al. Melanoma patients with positive sentinel nodes who did not undergo completion lymphadenectomy: a multiinstitutional study. Ann Surg Oncol. 2006;13(6):809-816. (Pubitemid 43727365)
28. Morton DL, Thompson JF, Cochran AJ, et al. Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med. 2006;355(13):1307-1317. (Pubitemid 44465459)
29. Morton DL, Cochran AJ, Thompson JF, et al. Sentinel node biopsy for earlystage melanoma: accuracy and morbidity in MSLT-I, an international multicenter trial. Ann Surg. 2005;242(3):302-311.
30. Vickers SM, Fouad MN. Enhancing Minority Participation in Clinical Trials (EMPACT). 2009. Grant support by The National Institute on Minority and Health Disparities (project No. 5RC2MD004797-004702).
31. Sateren WB, Trimble EL, Abrams J, et al. How sociodemographics, presence of oncology specialists, and hospital cancer programs affect accrual to cancer treatment trials. J Clin Oncol. 2002;20(8):2109-2117. (Pubitemid 34408802)
32. Klabunde CN, Keating NL, Potosky AL, et al. A population-based assessment of specialty physician involvement in cancer clinical trials. J Natl Cancer Inst. 103(5):384-397.
33. Ross SD. The CONSORT statement. JAMA. 1996;276(23):1877.
34. Rennie D. How to report randomized controlled trials. The CONSORT statement. JAMA. 1996;276(8):649.
35. Junker C, Egger M, Schneider M, et al. The CONSORT statement. JAMA. 1996;276(23):1876-1877.
36. Begg C, Cho M, Eastwood S, et al. Improving the quality of reporting of randomized controlled trials. TheCONSORT statement. JAMA. 1996;276(8):637-639. (Pubitemid 26278070)
37. Howard SC, Algra A,WarlowCP, et al. Potential consequences for recruitment, power, and external validity of requirements for additional risk factors for eligibility in randomized controlled trials in secondary prevention of stroke. Stroke. 2006;37(1):209-215. (Pubitemid 43732073)
38. Rothwell PM. Factors that can affect the external validity of randomised controlled trials. PLoS Clin Trials. 2006;1(1):e9.